A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
NCT02178397
Study timeline
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
What this registered study describes
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR is a interventional study listed under registry identifier NCT02178397. Its last published status is TERMINATED. Registry status does not establish that enrollment is currently open at every study site.
The published record lists 1 condition label(s), 2 intervention label(s), and 3 sponsor/collaborator entry or entries. The structured information below allows these links to be examined individually; intervention registration is not an efficacy claim.
Source: the original ClinicalTrials.gov study record. Always check the protocol, eligibility, dates, results (when posted), and contacts at the original source.
Conditions
Interventions
Sponsors & collaborators
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02178397 on ClinicalTrials.gov ↗How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.